AstraZeneca, Gilead merger doubted by Wall Street analysts
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
AstraZeneca (AZN) PT Raised to $60 at Cowen
June 10, 2020 8:45 AM EDTCowen analyst Steve Scala raised the price target on AstraZeneca (NYSE: AZN) to $60.00 (from $55.00) while maintaining an Outperform rating after updating the model following recent news including ASCO presentations, additional roxadustat data, and reports that AZN had contemplated a large-scale business... More
AstraZeneca (AZN) CEO Soriot Said to Have Called Gilead (GILD) CEO on May 9, Proposed Exploring Merger to O'Day on Call - Bloomberg
June 8, 2020 5:04 PM EDTAstraZeneca (NYSE: AZN) CEO Soriot Said to Have Called Gilead (NASDAQ: GILD) CEO on May 9, Proposed Exploring Merger to O'Day on Call - Bloomberg
... MoreGilead Sciences (GILD) Worth $120+ in Rumored Takeover - Piper Sandler
June 8, 2020 9:49 AM EDTPiper Sandler analyst Tyler Van Buren reiterated an Overweight rating and $90.00 price target on Gilead Sciences (NASDAQ: GILD) following rumor of a potential deal with AstraZeneca (NYSE: AZN). Van Buren sees Gilead worth $120+ per share in a deal.
The analyst commented, "The... More
